Median percent change from baseline of MBDA score and component concentrations
| Week 4 | Week 12 | |||||
|---|---|---|---|---|---|---|
| PBO | Filgotinib | Filgotinib ) | PBO | Filgotinib | Filgotinib | |
| (N=62) | 100mg QD | 200mg QD | (N=65) | 100mg QD | par 200mg QD | |
| (N=63) | (N=68) | (N=62) | (N=68) | |||
| MBDA SCORE | -1 | -20*** | -24*** | -5 | -19*** | -24*** |
| CRP | 15 | -57*** | -71*** | -8 | -66*** | -78*** |
| EGF | 14 | -18NS | -8NS | 0 | -10NS | 0NS |
| IL-6 | -15 | -34** | -60*** | -20 | -41** | -63*** |
| LEPTIN | 0 | 8NS | 18NS | 6 | 14NS | 23* |
| MMP-1 | 10 | -16*** | -24*** | -6 | -18** | -26*** |
| MMP-3 | 0 | -24** | -33*** | -9 | -25*** | -43*** |
| RESISTIN | 1 | -12** | -22*** | -1 | -15* | -16*** |
| SAA | 8 | -45*** | -65*** | 7 | -49*** | -67*** |
| TNF-RI | 0 | -11*** | -26*** | 0 | -11*** | -15*** |
| VCAM-1 | 5 | -10*** | -15*** | 0 | -8** | -16*** |
| VEGF | 3 | -16*** | -25*** | -2 | -16*** | -26*** |
| YKL-40 | 2 | -12* | -32*** | -7 | -17NS | -33*** |
p-values comparing % changes between filgotinib and PBO groups NS, p>0.05; *p<0.05; **p<0.01; ***p<0.001.